TEVATeva Pharmaceutical Industries Limited
Price
+124%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, demanding price, growth steady, the market undecided.
We are a biopharmaceutical company, enabled by a world-class generics business. For over 120 years, our commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, we are dedicated to addressing patients’ needs, now and in the future. We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world.
In the company’s own words · 10-K filed Feb 3, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Teva Pharmaceutical Industries Limited (TEVA) reported revenue of $4.14B in Q2 2026 (quarter ended Jun 30, 2026), down 0.8% from the same quarter a year earlier. That came with a gross margin of 52% and net loss of $576M. For the full year FY2025, revenue was $17.3B (+4.3% year on year) and net income $1.41B. Its largest product in Q2 2026 was Austedo at $676M, 38% of the disclosed total, just ahead of Generics Medicians Including Otc And Biosimilars at 37%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 16, 2026On September 16, 2026, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “Company”), issued €1,000,000,000 aggregate principal amount of 4.250% Senior Notes due 2033 (the “2033 Euro Notes”) and €500,000,000 aggregate …Material agreement entered · Form 8-K
- Sep 14, 2026On September 14, 2026, Teva Pharmaceutical Industries Ltd. (the “Company”) began trading its ordinary shares on the New York Stock Exchange, in lieu of its American depositary shares (“ADSs”), under the same ticker symbol under which the ADSs previously traded, “TEVA”Other event · Form 8-K
- Sep 11, 2026On September 9, 2026, Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”), Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”), Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and together with Teva Finance II and Teva Finance III, the “Issuers”) and, the Company …Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $1.78BThe company’s own SEC segment disclosure.
- Austedo$676.0M38%
- Generics Medicians Including Otc And Biosimilars$660.0M37%
- Ajovy$116.0M7%
- Other Products$84.0M5%
- Uzedy$77.0M4%
- COPAXONE$61.0M3%
- Other (3)$103.0M6%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #14 of 41 by RyuScore